Mylan and Pfizer have appointed Sanjeev Narula, current chief financial officer of Upjohn, a division of Pfizer, as incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Expected to close mid-2020, Viatris will have a portfolio of approximately 3,000 brands and molecules and a commercial presence in 165 countries.

Mr. Narula spent 16 years with Pfizer serving in several financial leadership positions, and has worked under the leadership of Pfizer’s Chief Financial Officer and Executive Vice President of Business Operations and Global Supply, Frank D’Amelio. At Upjohn, he worked closely with incoming Viatris CEO Michael Goettler and has developed a deep understanding of financial and commercial dynamics across key geographies, including emerging markets, particularly China. He also brings knowledge of the generic and branded pharmaceutical business.

Pfizer Chairman and CEO Dr. Albert Bourla said: “Sanjeev’s global experience, proven leadership, and deep industry knowledge will serve Viatris employees, customers and shareholders well. I am very confident that his commitment to excellence will be instrumental as the new company charts its path as a champion for global health.”